# Biocidal Products Regulation (BPR) — EU EU Regulation 528/2012 governs biocidal products — substances or mixtures intended to destroy, deter, render harmless, or control harmful organisms by chemical or biological means. For natural antimicrobials marketed in surface disinfection, industrial hygiene, or antimicrobial material applications (non-food-contact), BPR is the governing regime. ## The Two-Tier Approval Structure BPR operates at two levels: 1. **Active substance approval** at EU level — handled by the European Chemicals Agency (ECHA). The active substance must be listed in the Union List of Approved Active Substances before any product containing it can be authorised. 2. **Product authorisation** at member state or Union level — the formulated biocidal product (the specific mixture, concentration, and intended use) requires separate authorisation. A company cannot sell a biocidal product in the EU unless both its active substance is approved and its specific product is authorised. ## Product Types Relevant to Natural Antimicrobials BPR classifies biocidal products into 22 product types (PTs). The relevant categories for natural antimicrobial applications: | Product Type | Application | |---|---| | PT2 | Private area and public health area disinfectants | | PT4 | Food and feed area disinfectants | | PT9 | Fibre, leather, rubber, and polymerised material preservatives | | PT12 | Slimicides (industrial process water treatment) | A plant-extract antimicrobial used to sanitise fresh produce handling surfaces would fall under PT4. The same compound embedded in a polymer film to prevent mould growth would fall under PT9. Different product types require different data packages. ## The Article 95 List Article 95 of BPR requires that any supplier of an active substance or of a biocidal product containing that substance must be listed in a public register. This creates a direct competitive signal: companies can monitor which active substances are being developed by whom. ## Data Requirements The BPR dossier is substantial. For active substance approval, applicants must provide: - **Efficacy data:** minimum inhibitory concentration (MIC) and kill-time studies against target organisms - **Toxicological data:** acute toxicity, repeat-dose, genotoxicity, reproductive toxicity, dermal/inhalation endpoints - **Ecotoxicological data:** aquatic toxicity, soil organism toxicity, bioaccumulation - **Environmental fate:** biodegradation, soil sorption, volatility For natural-origin substances, the composition must be fully characterised. A plant extract is not a single compound — the full multi-constituent profile must be declared and tested. ## The Simplified Authorisation Route Substances that meet low-risk criteria (non-bioaccumulative, non-CMR, low toxicity) may qualify for Union Authorisation via a simplified procedure. This route is faster (180 days vs 365+ days for standard authorisation) and grants direct EU-wide market access without member state-level steps. For naturally derived antimicrobials with favourable toxicological profiles, the simplified route is worth evaluating early in regulatory strategy planning. ## Strategic Implication BPR approval creates a durable market access barrier. Unlike the GRAS self-determination pathway in the US, EU biocidal products cannot enter the market by declaration — they require positive regulatory action. The company that completes BPR approval first effectively controls the EU market for that specific active substance and use combination for the duration of the authorisation. Pairing BPR approval with patent protection on the formulation or delivery mechanism maximises the defensibility window. --- *Part of [[Natural Antimicrobials & Sustainable Materials MOC]]*